Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

[1]  J. Dignam,et al.  Comments on: Yin W, Di G, Zhou L, Lu J, Liu G, Wu J, Shen K, Han Q, Shen Z, Shao Z. Time-varying pattern of recurrence risk for Chinese breast cancer patients , 2009, Breast Cancer Research and Treatment.

[2]  J. Costantino,et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Perez,et al.  Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Winer,et al.  Advances in adjuvant endocrine therapy for postmenopausal women. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  L. V. van't Veer,et al.  Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Vanja Dukić,et al.  Bayesian Hierarchical Multiresolution Hazard Model for the Study of Time-Dependent Failure Patterns in Early Stage Breast Cancer. , 2007, Bayesian analysis.

[8]  N. Singpurwalla.  The Hazard Potential , 2006 .

[9]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Bingshu E. Chen,et al.  Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast Cancer , 2006, Breast Cancer Research and Treatment.

[11]  Donald A. Berry,et al.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .

[12]  Thomas J. Smith,et al.  Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer , 2005, ACP journal club.

[13]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[14]  J. Cuzick,et al.  An exploration of relapse data by hazard rate as a means of developing biological insights into the natural history and treatment of breast cancer: Data from the ’Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial and the Milan Institute database , 2005 .

[15]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[16]  G. Robbins,et al.  Curability of patients with invasive breast carcinoma based on a 30-year study , 1977, World Journal of Surgery.

[17]  D. Berry.  Breast cancer heterogeneity may explain peaks in recurrence. , 2005, International journal of surgery.

[18]  Rosalba Miceli,et al.  Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy , 2005, Breast Cancer Research and Treatment.

[19]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[20]  N. Wolmark,et al.  Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. , 2004, Journal of the National Cancer Institute.

[21]  J. Bryant,et al.  Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials , 2004, The Lancet.

[22]  K. Hess,et al.  Estrogen Receptors and Distinct Patterns of Breast Cancer Relapse , 2003, Breast Cancer Research and Treatment.

[23]  S. Hilsenbeck,et al.  Time-dependence of hazard ratios for prognostic factors in primary breast cancer , 2004, Breast Cancer Research and Treatment.

[24]  J. Bryant,et al.  S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer , 2004, Breast Cancer Research and Treatment.

[25]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[26]  Gordon Johnston,et al.  Statistical Models and Methods for Lifetime Data , 2003, Technometrics.

[27]  A parametric model for long‐term follow‐up data from phase III breast cancer clinical trials , 2003, Statistics in medicine.

[28]  O. Aalen,et al.  Understanding the shape of the hazard rate: A proce ss point of view , 2002 .

[29]  R. Demicheli,et al.  Does surgery modify growth kinetics of breast cancer micrometastases? , 2001, British Journal of Cancer.

[30]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[31]  J. Bryant,et al.  Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. , 2001, Journal of the National Cancer Institute.

[32]  D. Wickerham,et al.  Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  O. Aalen,et al.  Understanding the shape of the hazard rate: a process point of view (With comments and a rejoinder by the authors) , 2001 .

[34]  K R Hess,et al.  Hazard function estimators: a simulation study. , 1999, Statistics in medicine.

[35]  D J Ferguson,et al.  Dormancy of mammary carcinoma after mastectomy. , 1999, Journal of the National Cancer Institute.

[36]  B Fisher,et al.  Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. , 1997, Journal of the National Cancer Institute.

[37]  D J Sargent,et al.  A Flexible Approach to Time-varying Coefficients in the Cox Regression Setting , 1997, Lifetime data analysis.

[38]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[39]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Redmond,et al.  Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T M Therneau,et al.  Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. , 1995, Biometrics.

[42]  K R Hess,et al.  Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. , 1994, Statistics in medicine.

[43]  H. Müller,et al.  Hazard rate estimation under random censoring with varying kernels and bandwidths. , 1994, Biometrics.

[44]  Robert Gray,et al.  Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .

[45]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[46]  C. Redmond,et al.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.

[47]  J. Lawless.  Statistical Models and Methods for Lifetime Data , 1983 .

[48]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[49]  V T Farewell,et al.  The analysis of failure times in the presence of competing risks. , 1978, Biometrics.

[50]  D.,et al.  Regression Models and Life-Tables , 2022 .